RECRUITING

Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center

Conditions

Diabetic Foot Ulcer Venous Leg Ulcer Surgical Wound Dehiscence Traumatic Wounds

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Prospective, single-blinded, single-center, parallel group, randomized controlled trial (RCT) to assess rate and frequency of wound healing and associated financial savings, when using Medaxis debritom+ versus standard of care as a choice of debridement method, where both arms follow normal wound care practice in use of advanced wound care treatments.

Official Title

Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center

Quick Facts

Study Start:2021-11-29

Study Completion:2025-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04920253

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. At least 18 years old. 2. The index wound (i.e. current episode of the wound or ulceration) has been present for greater than 4 weeks prior to SV 1 and has had less than 1 year of documented medical treatment, as of the subject's consent for the study participation. 3. The index wound is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1. 4. Subject understands and is willing to participate in the clinical study and can comply with weekly visits. 5. Subject must have read and signed the IRB approved Informed Consent Form (ICF) before study specific screening procedures that are not standard of care are undertaken. 6. Presence of diabetic foot ulcer (DFU) that meets all of the following features: 7. Wagner Grade 1 or 2 (see Appendix A for definitions), including wounds that extend to the ligament, tendon, joint capsule or fascia 8. Without abscess or osteomyelitis 9. The index ulcer will be the largest ulcer if two or more DFUs are present and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2cm distant from index ulcer (edge to edge). 10. The index ulcer has been offloaded for at least 14 days prior to randomization 11. Adequate circulation to the affected foot as documented by a Clarifi SFDI Vascular Assessment Tool, or an Ankle Brachial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed, evaluating for bi-phasic dorsalis pedis and posterior tibial vessels at the level of the ankle within 3 months of SV1 or if monophasic wave forms present must have adequate micro circulation as evidenced by Clarifi SFDI Vascular Assessment Tool. Note: A documented record of an ABI test performed using the index ulcer leg, within 3 months of SV1 is acceptable for the purposes of this study. Otherwise, this must be completed in the Screening Visit. Acceptable alternatives include arterial Doppler ultrasound evaluating vessels at the level of the ankle, or documented adequate microcirculation as determined by a Clarifi SFDI Vascular Assessment Tool. 12. All wounds using the CEAP VLU Classification, except for those in the exclusion criteria. (See Appendix A for definitions) 13. The index ulcer will be the largest ulcer if two or more VLUs are present and will be the only one evaluated in the study. If other Ulcerations are present on the same leg, they must be more than 2cm distant from index ulcer. 14. Adequate circulation to the affected foot as documented by a Clarifi SFDI Vascular Assessment Tool, or an Ankle Brachial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed, evaluating for bi-phasic dorsalis pedis and posterior tibial vessels at the level of the ankle within 3 months of SV1 or if monophasic wave forms present must have adequate micro circulation as evidenced by Clarifi SFDI Vascular Assessment Tool. Note: A documented record of an ABI test performed using the index ulcer leg, within 3 months of SV1 is acceptable for the purposes of this study. Otherwise, this must be completed in the Screening Visit. Acceptable alternatives include arterial Doppler ultrasound evaluating vessels at the level of the ankle, or documented adequate microcirculation as determined by a Clarifi SFDI Vascular Assessment Tool. 15. All wounds using the Sandy Grading System, except those in the exclusion criteria. (See Appendix A for definitions) 16. All wounds as per the CDC Surgical Wound Classification, with the exception of Class IV or dirty infected wounds, SSI - Deep incisional and organ space. (See Appendix A for definitions)	1. The index wound, in the opinion of the investigator, is suspicious for cancer or have a positive carcinoma diagnosis. 2. Subject has a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the wound surface within 1 month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study. 3. Subject is taking a selective COX-2 inhibitor, such as Celecoxib, for any condition. 4. Subject is on any investigational drug(s) or therapeutic device(s) within 30 days preceding SV1. 5. History of radiation at the wound site (regardless of time since last radiation treatment). 6. Index wound has been previously treated or will need to be treated with any prohibited therapies (See Section 6 of this protocol for a list of prohibited medications and therapies). 7. Subject has a previous diagnosis of HIV, Hepatitis C, or other contagious diseases. 8. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or the subject has a known history of poor adherence with medical treatment. 9. Subject is pregnant or breast-feeding. 10. Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 % within 90 days of randomization. 11. Subject has end-stage renal disease as evidenced by a serum creatinine \> 3.0mg/dL within 6 months of randomization. 12. BMI \>55 13. PAR experiences a \>30% change between SV1 and SV2 DFU 14. Wagner 2 wounds that require debridement of bone. 15. Osteomyelitis or bone infection of the affected foot as verified by x-ray, CAT Scan, or MRI within 30 days prior to randomization (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision). 16. Exclude 1. Secondary post thrombotic 2. Venous Obstruction 3. Venous Obstruction with reflux 4. Lipodermato sclerosis or atrophic blanche 17. Osteomyelitis or bone infection of the affected leg as verified by x-ray, CAT Scan, or MRI within 30 days prior to randomization (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision). 18. Using the Sandy Grading System for Surgical Wound Dehiscence: Wounds Grade 3 where organs are exposed, and 3a, where the infection is severe as deemed by the Principal Investigator. 19. Using CDC Surgical Wound Classification, exclude 1. Class IV - dirty infected wounds 2. SSI - Deep incisional and organ space

Inclusion Criteria

Exclusion Criteria

1. At least 18 years old.
2. The index wound (i.e. current episode of the wound or ulceration) has been present for greater than 4 weeks prior to SV 1 and has had less than 1 year of documented medical treatment, as of the subject's consent for the study participation.
3. The index wound is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1.
4. Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
5. Subject must have read and signed the IRB approved Informed Consent Form (ICF) before study specific screening procedures that are not standard of care are undertaken.
6. Presence of diabetic foot ulcer (DFU) that meets all of the following features:
7. Wagner Grade 1 or 2 (see Appendix A for definitions), including wounds that extend to the ligament, tendon, joint capsule or fascia
8. Without abscess or osteomyelitis
9. The index ulcer will be the largest ulcer if two or more DFUs are present and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2cm distant from index ulcer (edge to edge).
10. The index ulcer has been offloaded for at least 14 days prior to randomization
11. Adequate circulation to the affected foot as documented by a Clarifi SFDI Vascular Assessment Tool, or an Ankle Brachial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed, evaluating for bi-phasic dorsalis pedis and posterior tibial vessels at the level of the ankle within 3 months of SV1 or if monophasic wave forms present must have adequate micro circulation as evidenced by Clarifi SFDI Vascular Assessment Tool. Note: A documented record of an ABI test performed using the index ulcer leg, within 3 months of SV1 is acceptable for the purposes of this study. Otherwise, this must be completed in the Screening Visit. Acceptable alternatives include arterial Doppler ultrasound evaluating vessels at the level of the ankle, or documented adequate microcirculation as determined by a Clarifi SFDI Vascular Assessment Tool.
12. All wounds using the CEAP VLU Classification, except for those in the exclusion criteria. (See Appendix A for definitions)
13. The index ulcer will be the largest ulcer if two or more VLUs are present and will be the only one evaluated in the study. If other Ulcerations are present on the same leg, they must be more than 2cm distant from index ulcer.
14. Adequate circulation to the affected foot as documented by a Clarifi SFDI Vascular Assessment Tool, or an Ankle Brachial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed, evaluating for bi-phasic dorsalis pedis and posterior tibial vessels at the level of the ankle within 3 months of SV1 or if monophasic wave forms present must have adequate micro circulation as evidenced by Clarifi SFDI Vascular Assessment Tool. Note: A documented record of an ABI test performed using the index ulcer leg, within 3 months of SV1 is acceptable for the purposes of this study. Otherwise, this must be completed in the Screening Visit. Acceptable alternatives include arterial Doppler ultrasound evaluating vessels at the level of the ankle, or documented adequate microcirculation as determined by a Clarifi SFDI Vascular Assessment Tool.
15. All wounds using the Sandy Grading System, except those in the exclusion criteria. (See Appendix A for definitions)
16. All wounds as per the CDC Surgical Wound Classification, with the exception of Class IV or dirty infected wounds, SSI - Deep incisional and organ space. (See Appendix A for definitions)

1. The index wound, in the opinion of the investigator, is suspicious for cancer or have a positive carcinoma diagnosis.
2. Subject has a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the wound surface within 1 month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study.
3. Subject is taking a selective COX-2 inhibitor, such as Celecoxib, for any condition.
4. Subject is on any investigational drug(s) or therapeutic device(s) within 30 days preceding SV1.
5. History of radiation at the wound site (regardless of time since last radiation treatment).
6. Index wound has been previously treated or will need to be treated with any prohibited therapies (See Section 6 of this protocol for a list of prohibited medications and therapies).
7. Subject has a previous diagnosis of HIV, Hepatitis C, or other contagious diseases.
8. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or the subject has a known history of poor adherence with medical treatment.
9. Subject is pregnant or breast-feeding.
10. Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 % within 90 days of randomization.
11. Subject has end-stage renal disease as evidenced by a serum creatinine \> 3.0mg/dL within 6 months of randomization.
12. BMI \>55
13. PAR experiences a \>30% change between SV1 and SV2 DFU
14. Wagner 2 wounds that require debridement of bone.
15. Osteomyelitis or bone infection of the affected foot as verified by x-ray, CAT Scan, or MRI within 30 days prior to randomization (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision).
16. Exclude
1. Secondary post thrombotic
2. Venous Obstruction
3. Venous Obstruction with reflux
4. Lipodermato sclerosis or atrophic blanche
17. Osteomyelitis or bone infection of the affected leg as verified by x-ray, CAT Scan, or MRI within 30 days prior to randomization (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision).
18. Using the Sandy Grading System for Surgical Wound Dehiscence: Wounds Grade 3 where organs are exposed, and 3a, where the infection is severe as deemed by the Principal Investigator.
19. Using CDC Surgical Wound Classification, exclude
1. Class IV - dirty infected wounds
2. SSI - Deep incisional and organ space

Contacts and Locations

Study Contact

Sharona Segal-Leibovich

CONTACT

646-369-1570

ssegal-leibovich@namsa.com

Amy Jo Johnson

CONTACT

amyjo.johnson@medaxis.us

Principal Investigator

Melvin B Price, DPM

PRINCIPAL_INVESTIGATOR

MCR Health Inc.

Study Locations (Sites)

MCR Health, Inc.

Bradenton, Florida, 34208

United States

Collaborators and Investigators

Sponsor: Medaxis, LLC

Melvin B Price, DPM, PRINCIPAL_INVESTIGATOR, MCR Health Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-29

Study Completion Date2025-12

Study Record Updates

Study Start Date2021-11-29

Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

Diabetic Foot Ulcer
Venous Leg Ulcer
Surgical Wound Dehiscence
Traumatic Wounds